BERKELEY, Calif., April 01, 2019 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (NASDAQ: ADRO) today announced that Stephen T. Isaacs,
chairman, president and chief executive officer of Aduro, is scheduled to present at the H.C. Wainwright Global Life Sciences
Conference in London, United Kingdom on Monday, April 8th at 9:30 am GMT.
To access the live webcasts and subsequent archived recordings of these and other company presentations, please visit the
investor section of Aduro's website at www.aduro.com. The archived webcasts will remain available for replay on Aduro’s website for 30
days.
About Aduro
Aduro Biotech, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of
therapies that are designed to harness the body's natural immune system for the treatment of patients with challenging diseases.
Aduro’s product candidates in the Stimulator of Interferon Genes (STING) and A Proliferation Inducing Ligand (APRIL) pathways are
being investigated in cancer, autoimmune and inflammatory diseases. ADU-S100 (MIW815), which potentially activates the
intracellular STING receptor for a potent tumor-specific immune response, is being evaluated in patients with cutaneously
accessible metastatic solid tumors or lymphomas. BION-1301, a fully blocking monoclonal antibody that blocks APRIL binding to both
the BCMA and TACI receptors, is being evaluated in multiple myeloma and as a potential treatment for IgA nephropathy. Aduro is
collaborating with a number of leading global pharmaceutical companies to help expand and drive its product pipeline. For more
information, please visit www.aduro.com.
